KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...

Fintel reports that on January 7, 2025, TD Cowen initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Buy recommendation. Analyst Price Forecast Suggests 224.00% Upside As of December ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of ...

Barclays PLC increased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 418.5% during the third quarter, Holdings Channel.com reports. The fund owned 67,222 ...

TD Cowen initiated coverage of KalVista (KALV) with a Buy rating and $30 price target The firm cites sebetralstat’s opportunity as the first oral acute therapy for hereditary angioedema attacks ...

JonesResearch lowered the firm’s price target on KalVista (KALV) to $33 from $35 and keeps a Buy rating on the shares. The firm incorporated the company’s fiscal Q2 updates and recent royalty ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO).

January 16, 2025, 04:48 am ET, BY Robert S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short KALV slightly ...

KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted ...